26.07
+6.67%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rapport Therapeutics
From its filings with the US Securities and Exchange Commission
Rapport Therapeutics is based in Boston, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker RAPP. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $111.5m. At that date it held total assets of $512.4m and shareholders' equity of $484.7m.
We are a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders. Our foundational science has elucidated the complexities of neuronal receptor biology and enables us to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor associated proteins (“RAPs”), the latter of which play crucial roles in regulating receptor expression and function. We believe that our deep expertise in RAP biology provides an opportunity for us to interrogate previously inaccessible targets and develop neurological and psychiatric drugs that are specific for receptor variants and neuroanatomical regions associated with certain diseases. Most neuroactive drugs lack this specificity, often resulting in undesired and intolerable side effects. Leveraging our expertise, we are developing a portfolio of precision product candidates that we believe has the potential to transform the standard of care of many neurological and psychiatric disorders.
Quoted from its 10-K, filed 10 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Jun 2024
- Employees
- 84
- Website
- rapportrx.com ↗
- Head office
- 99 HIGH STREET, BOSTON, MA, 02110
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Steven PaulIndependent Chairman of the Board$671,241
- Mr. Abraham CeesayPresident, Chief Executive Officer, Director, since 2023$9.8m
- Mr. Troy IgnelziChief Financial Officer$2.5m
- Ms. Cheryl GaultChief Operating Officer$1.8m
- Mr. David BredtChief Scientific Officer, since 2022
- Dr. Jeffrey SevignyChief Medical Officer
- Dr. Swamy YeleswaramChief Development Officer
- Mr. Reid HuberDirector, since 2022$26,699
- Dr. James HealeyIndependent Director$34,533
- Dr. John MaraganoreIndependent Director$830,762
- Mr. Robert PerezIndependent Director$593,519
- Dr. Ramiro SanchezIndependent Director$592,921
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Boston, Massachusetts with 84 employees.
- Focuses on developing a new class of precision neuromedicines for CNS disorders.
- Advances a pipeline of therapeutic programs for conditions including epilepsy, pain, and bipolar disorder.
Weaknesses
- The company has a small employee count of 84, which may limit operational capacity.
- The company is newly public with an IPO on 2024-06-07, indicating limited market history.
- The company's pipeline is focused on specific CNS disorders, which may limit market reach.
Opportunities
- The company's focus on CNS disorders presents opportunities in a growing healthcare sector.
- The development of RAP-219 as a clinical-stage small molecule could lead to significant market opportunities.
- The company's targeting of TARPy8 associated with neuronal AMPAR may provide a competitive edge.
Threats
- The company's reliance on a narrow pipeline of therapeutic programs may increase business risk.
- The pharmaceutical industry is highly competitive with significant regulatory hurdles.
- The company's small size may make it vulnerable to market fluctuations and competition.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.